Tests vepugratinib with standard drugs for bladder cancer that has spread
Tests vepugratinib with other cancer drugs in adults with advanced bladder cancer.
Plain-language title generated from the registry record
Registry title: A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Key facts
- Where
- Bad Saarow, Bielefeld, Bonn, Cologne, Dresden, Duisburg, Düsseldorf, Erlangen, Essen, Frankfurt, Freiburg im Breisgau, Greifswald, Hamburg, Heidelberg, Homburg, Koblenz, Lübeck, Munich, Münster, Nuremberg, Nürtingen, Rostock, Tübingen, Ulm, and Würzburg, GermanySee the 25 sites
- Phase
- Phase 3
Where in Germany
- HELIOS Klinikum Bad SaarowBad Saarow, GermanyNot yet recruiting
- Evangelisches Krankenhaus Bielefeld - JohannesstiftBielefeld, GermanyNot yet recruiting
- Johanniter KrankenhausBonn, GermanyNot yet recruiting
- Studienzentrum Bayenthal Urologische Partnerschaft KölnCologne, GermanyNot yet recruiting
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet DresdenDresden, GermanyNot yet recruiting
- Urologicum Duisburg Fachärztesozietät - WalsumDuisburg, GermanyNot yet recruiting
- Universitaetsklinikum DuesseldorfDüsseldorf, GermanyNot yet recruiting
- Universitaetsklinikum ErlangenErlangen, GermanyNot yet recruiting
- Universitaetsklinikum - EssenEssen, GermanyNot yet recruiting
- Krankenhaus Nordwest GmbHFrankfurt, GermanyNot yet recruiting
- Universitaetsklinikum FreiburgFreiburg im Breisgau, GermanyNot yet recruiting
- Universitätsmedizin GreifswaldGreifswald, GermanyNot yet recruiting
- Universitaetsklinikum Hamburg-EppendorfHamburg, GermanyNot yet recruiting
- NCTHeidelberg, GermanyNot yet recruiting
- Universitaetsklinikum des SaarlandesHomburg, GermanyNot yet recruiting
- InVO Institut für Versorgungsforschung in der OnkologieKoblenz, GermanyNot yet recruiting
- Universitätsklinikum Schleswig-HolsteinLübeck, GermanyNot yet recruiting
- Klinikum rechts der Isar der Technischen Universität MünchenMunich, GermanyNot yet recruiting
- Universitätsklinikum Münster - Albert Schweitzer CampusMünster, GermanyNot yet recruiting
- Klinikum Nürnberg NordNuremberg, GermanyNot yet recruiting
- Studienpraxis UrologieNürtingen, GermanyNot yet recruiting
- Universitätsmedizin RostockRostock, GermanyNot yet recruiting
- Universitaetsklinikum TuebingenTübingen, GermanyNot yet recruiting
- Universitaetsklinikum UlmUlm, GermanyNot yet recruiting
- Universitaetsklinikum WuerzburgWürzburg, GermanyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07218380EU 2025-522855-25-00
- Record updated
- 7 October 2026
- Original description
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.Read full original descriptionShow less
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.
Study participation could last up to approximately 6 years.
Inclusion: Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present; Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer; Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; Have adequate laboratory parameters.
Exclusion: Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC); Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events ([CTCAE] version 5.0) from prior neoadjuvant or adjuvant systemic therapy; Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease; Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening; Have ongoing sensory or motor neuropathy of Grade 2 or higher.